197 related articles for article (PubMed ID: 21199653)
1. Inosine triphosphate protects against ribavirin-induced adenosine triphosphate loss by adenylosuccinate synthase function.
Hitomi Y; Cirulli ET; Fellay J; McHutchison JG; Thompson AJ; Gumbs CE; Shianna KV; Urban TJ; Goldstein DB
Gastroenterology; 2011 Apr; 140(4):1314-21. PubMed ID: 21199653
[TBL] [Abstract][Full Text] [Related]
2. Effects of ribavirin/sofosbuvir treatment and ITPA phenotype on endogenous purines.
Jimmerson LC; Clayton CW; MaWhinney S; Meissner EG; Sims Z; Kottilil S; Kiser JJ
Antiviral Res; 2017 Feb; 138():79-85. PubMed ID: 27956135
[TBL] [Abstract][Full Text] [Related]
3. Tolerability of Erythrocyte Ribavirin Triphosphate Concentrations Depends on the ITPA Genotype.
Tanaka Y; Inoue A; Mizunuma T; Matsumura H; Yokomori H; Komiyama T; Otori K
Ther Drug Monit; 2019 Aug; 41(4):497-502. PubMed ID: 30817703
[TBL] [Abstract][Full Text] [Related]
4. Association of ITPA polymorphisms rs6051702/rs1127354 instead of rs7270101/rs1127354 as predictor of ribavirin-associated anemia in chronic hepatitis C treated patients.
D'Avolio A; De Nicolò A; Cusato J; Ciancio A; Boglione L; Strona S; Cariti G; Troshina G; Caviglia GP; Smedile A; Rizzetto M; Di Perri G
Antiviral Res; 2013 Oct; 100(1):114-9. PubMed ID: 23933495
[TBL] [Abstract][Full Text] [Related]
5. Rapidity and Severity of Hemoglobin Decreasing Associated with Erythrocyte Inosine Triphosphatase Activity and ATP Concentration during Chronic Hepatitis C Treatment.
Tanaka Y; Tamura Y; Yokomori H; Komiyama T
Biol Pharm Bull; 2016; 39(4):615-9. PubMed ID: 27040635
[TBL] [Abstract][Full Text] [Related]
6. Inosine Triphosphate Pyrophosphatase Dephosphorylates Ribavirin Triphosphate and Reduced Enzymatic Activity Potentiates Mutagenesis in Hepatitis C Virus.
Nyström K; Wanrooij PH; Waldenström J; Adamek L; Brunet S; Said J; Nilsson S; Wind-Rotolo M; Hellstrand K; Norder H; Tang KW; Lagging M
J Virol; 2018 Oct; 92(19):. PubMed ID: 30045981
[TBL] [Abstract][Full Text] [Related]
7. Induction of inosine triphosphatase activity during ribavirin treatment for chronic hepatitis C.
Tanaka Y; Yokomori H; Otori K
Clin Chim Acta; 2018 Jul; 482():16-20. PubMed ID: 29580856
[TBL] [Abstract][Full Text] [Related]
8. Variant Inosine Triphosphatase Phenotypes Are Associated With Increased Ribavirin Triphosphate Levels.
Jimmerson LC; Urban TJ; Truesdale A; Baouchi-Mokrane F; Kottilil S; Meissner EG; Sims Z; Langness JA; Hodara A; Aquilante CL; Kiser JJ
J Clin Pharmacol; 2017 Jan; 57(1):118-124. PubMed ID: 27349952
[TBL] [Abstract][Full Text] [Related]
9. The effect of ITPA polymorphisms on the enzyme kinetic properties of human erythrocyte inosine triphosphatase toward its substrates ITP and 6-Thio-ITP.
Bakker JA; Lindhout M; Habets DD; van den Wijngaard A; Paulussen AD; Bierau J
Nucleosides Nucleotides Nucleic Acids; 2011 Nov; 30(11):839-49. PubMed ID: 22060550
[TBL] [Abstract][Full Text] [Related]
10. Inosine triphosphate pyrophosphohydrolase activity: more accurate predictor for ribavirin-induced anemia in hepatitis C infected patients than ITPA genotype.
Peltenburg NC; Bakker JA; Vroemen WH; de Knegt RJ; Leers MP; Bierau J; Verbon A
Clin Chem Lab Med; 2015 Nov; 53(12):2021-9. PubMed ID: 25968438
[TBL] [Abstract][Full Text] [Related]
11. Role of ITPA gene polymorphism in ribavirin-induced anemia and thrombocytopenia in Egyptian patients with chronic hepatitis C.
Nemr N; Kishk R; Mandour M
Indian J Gastroenterol; 2016 Jan; 35(1):7-13. PubMed ID: 26880169
[TBL] [Abstract][Full Text] [Related]
12. ITPA Polymorphisms Are Associated with Hematological Side Effects during Antiviral Therapy for Chronic HCV Infection.
Maan R; van der Meer AJ; Brouwer WP; Plompen EP; Sonneveld MJ; Roomer R; van der Eijk AA; Groothuismink ZM; Hansen BE; Veldt BJ; Janssen HL; Boonstra A; de Knegt RJ
PLoS One; 2015; 10(10):e0139317. PubMed ID: 26441325
[TBL] [Abstract][Full Text] [Related]
13. The role of ITPA and ribavirin transporter genes polymorphisms in prediction of ribavirin-induced anaemia in chronic hepatitis C Egyptian patients.
El Desoky ES; Abdelhafez AT; Cusato J; Kamel SI; Hussein AM; De Nicolo A; Di Perri G; D'Avolio A
Clin Exp Pharmacol Physiol; 2017 Sep; 44(9):965-968. PubMed ID: 28543275
[TBL] [Abstract][Full Text] [Related]
14. Variants in the ITPA gene protect against ribavirin-induced hemolytic anemia and decrease the need for ribavirin dose reduction.
Thompson AJ; Fellay J; Patel K; Tillmann HL; Naggie S; Ge D; Urban TJ; Shianna KV; Muir AJ; Fried MW; Afdhal NH; Goldstein DB; McHutchison JG
Gastroenterology; 2010 Oct; 139(4):1181-9. PubMed ID: 20547162
[TBL] [Abstract][Full Text] [Related]
15. Impact of inosine triphosphatase gene variants on the risk of anemia in HIV/hepatitis C virus-coinfected patients treated for chronic hepatitis C.
Rallón NI; Morello J; Labarga P; Benito JM; Rodríguez-Nóvoa S; Vispo E; Barreiro P; Castro MÁ; Aguirrebengoa K; Pineda JA; Miralles P; Tellez MJ; Portu J; Miralles C; Ocampo A; Soriano V;
Clin Infect Dis; 2011 Dec; 53(12):1291-5. PubMed ID: 22028438
[TBL] [Abstract][Full Text] [Related]
16. Inosine triphosphatase allele frequency and association with ribavirin-induced anaemia in Brazilian patients receiving antiviral therapy for chronic hepatitis C.
Delvaux N; Costa VD; Costa MM; Villar LM; Coelho HS; Esberard EB; Flores PP; Brandão-Mello CE; Villela-Nogueira CA; Almeida AJ; Lampe E
Mem Inst Oswaldo Cruz; 2015 Aug; 110(5):636-43. PubMed ID: 26154744
[TBL] [Abstract][Full Text] [Related]
17. Modeling Ribavirin-Induced Anemia in Patients with Chronic Hepatitis C Virus.
Wu LS; Jimmerson LC; MacBrayne CE; Kiser JJ; D'Argenio DZ
CPT Pharmacometrics Syst Pharmacol; 2016 Feb; 5(2):65-73. PubMed ID: 26933517
[TBL] [Abstract][Full Text] [Related]
18. Gene expression profiles associated with anaemia and ITPA genotypes in patients with chronic hepatitis C (CH-C).
Birerdinc A; Estep M; Afendy A; Stepanova M; Younossi I; Baranova A; Younossi ZM
J Viral Hepat; 2012 Jun; 19(6):414-22. PubMed ID: 22571903
[TBL] [Abstract][Full Text] [Related]
19. Inosine triphosphatase deficiency helps predict anaemia, anaemia management and response in chronic hepatitis C therapy.
Clark PJ; Aghemo A; Degasperi E; Galmozzi E; Urban TJ; Vock DM; Patel K; Thompson AJ; Rumi MG; D'Ambrosio R; Muir AJ; Colombo M
J Viral Hepat; 2013 Dec; 20(12):858-66. PubMed ID: 24304455
[TBL] [Abstract][Full Text] [Related]
20. Low membrane protein sulfhydrils but not G6PD deficiency predict ribavirin-induced hemolysis in hepatitis C.
Grattagliano I; Russmann S; Palmieri VO; Jüni P; Bihl F; Portincasa P; Palasciano G; Lauterburg BH
Hepatology; 2004 May; 39(5):1248-55. PubMed ID: 15122753
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
